Anticoagulation for intermittent hemodialysis (Q33931031)

30 July 2017

1 reference

title

Anticoagulation for intermittent hemodialysis (English)

1 reference

30 July 2017

1 reference

1 reference

Ouseph R

1

1 reference

30 July 2017

Ward RA

series ordinal

2

1 reference

30 July 2017

publication date

1 May 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

13

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

181-187

1 reference

Sequence variation in heparin octasaccharides with high affinity for antithrombin III.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Monitoring heparin therapy in hemodialysis. A report on the activated whole blood coagulation time tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Prediction of anticoagulation during hemodialysis by population kinetics and an artificial neural network.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Clotting by heparin of hemoaccess for hemodialysis in an end-stage renal disease patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Heparin free dialysis: comparative data and results in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Low thrombogenicity of polyethylene glycol-grafted cellulose membranes does not influence heparin requirements in hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Delayed elimination of enoxaparine in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

A single dose of dalteparin effectively prevents clotting during haemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Reduced lipid concentrations during four years of dialysis with low molecular weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

The development of hirudin as an antithrombotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

A comparison between the use of recombinant hirudin and heparin during hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

In vitro study of r-hirudin permeability through membranes of different haemodialysers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1525-139X.2000.00052.X

10.1046/J.1525-139X.2000.00052.X

21 January 2018

Identifiers

DOI

1 reference

release_o3auhx6hjnewzjl6w76h447h6e

30 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o3auhx6hjnewzjl6w76h447h6e

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference